Skip to main content

Shulman Joseph's Form 4 filing

Rhythm Pharmaceuticals, Inc. (RYTM) · filed Dec 29, 2023

Accession no.
0001104659-23-130499
Filed
Dec 29, 2023
Trade date
Dec 27-28, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $647.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shulman JosephCIK 0001909855Officer (Chief Technical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 27, 2023Common StockMOption exerciseAcquired+2,400$21.38+$51,3126,141Direct
Dec 27, 2023Common StockSSaleDisposed−5,015$50.01F2−$250,800.151,126Direct
Dec 28, 2023Common StockMOption exerciseAcquired+6,800$21.38+$145,3847,926Direct
Dec 28, 2023Common StockSSaleDisposed−7,926$50.00F3−$396,3000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 27, 2023Common StockMOption exerciseDisposed−2,400$0.00$082,600Direct
Dec 28, 2023Common StockMOption exerciseDisposed−6,800$0.00$075,800Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)